 Michelle Haas
Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Latent Tuberculosis | 8 | 2021 | 69 | 3.040 |
Why?
| | Antitubercular Agents | 5 | 2024 | 206 | 1.030 |
Why?
| | Isoniazid | 3 | 2021 | 63 | 0.900 |
Why?
| | Tuberculosis | 3 | 2024 | 279 | 0.810 |
Why?
| | Tuberculin Test | 2 | 2024 | 36 | 0.740 |
Why?
| | Interferon-gamma Release Tests | 2 | 2024 | 32 | 0.730 |
Why?
| | Health Systems Plans | 1 | 2020 | 3 | 0.690 |
Why?
| | Diagnostic Tests, Routine | 1 | 2019 | 110 | 0.590 |
Why?
| | Directly Observed Therapy | 1 | 2018 | 16 | 0.590 |
Why?
| | Rifampin | 4 | 2021 | 84 | 0.500 |
Why?
| | Mycobacterium Infections | 1 | 2016 | 63 | 0.480 |
Why?
| | Mass Screening | 2 | 2020 | 1287 | 0.470 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2016 | 127 | 0.460 |
Why?
| | Mycobacterium tuberculosis | 1 | 2018 | 314 | 0.460 |
Why?
| | Receptors, CXCR5 | 1 | 2014 | 21 | 0.460 |
Why?
| | Receptors, CXCR4 | 1 | 2014 | 86 | 0.440 |
Why?
| | Lymphoid Tissue | 1 | 2014 | 75 | 0.440 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 233 | 0.410 |
Why?
| | Mycobacterium Infections, Nontuberculous | 3 | 2024 | 363 | 0.400 |
Why?
| | Nontuberculous Mycobacteria | 2 | 2024 | 205 | 0.390 |
Why?
| | HIV-1 | 2 | 2014 | 864 | 0.350 |
Why?
| | Drug Administration Schedule | 3 | 2021 | 786 | 0.310 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2014 | 1091 | 0.290 |
Why?
| | Emigrants and Immigrants | 2 | 2020 | 136 | 0.290 |
Why?
| | Drug Therapy, Combination | 2 | 2021 | 1066 | 0.270 |
Why?
| | HIV Infections | 2 | 2016 | 2836 | 0.220 |
Why?
| | Refugees | 1 | 2024 | 75 | 0.210 |
Why?
| | Anti-Infective Agents | 2 | 2015 | 255 | 0.180 |
Why?
| | Anti-Bacterial Agents | 4 | 2024 | 1809 | 0.170 |
Why?
| | Emigration and Immigration | 1 | 2020 | 46 | 0.170 |
Why?
| | Tuberculin | 1 | 2019 | 8 | 0.160 |
Why?
| | Humans | 20 | 2024 | 137585 | 0.160 |
Why?
| | Georgia | 1 | 2019 | 86 | 0.160 |
Why?
| | Caliciviridae Infections | 1 | 2019 | 20 | 0.150 |
Why?
| | Single-Domain Antibodies | 1 | 2019 | 15 | 0.150 |
Why?
| | Norovirus | 1 | 2019 | 26 | 0.150 |
Why?
| | United States | 5 | 2024 | 14841 | 0.140 |
Why?
| | Internal Medicine | 1 | 2020 | 265 | 0.140 |
Why?
| | Skin Diseases, Bacterial | 2 | 2015 | 21 | 0.140 |
Why?
| | Receptors, HIV | 2 | 2014 | 24 | 0.140 |
Why?
| | Female | 13 | 2024 | 73304 | 0.140 |
Why?
| | Nitrofurantoin | 1 | 2017 | 8 | 0.130 |
Why?
| | Anti-Infective Agents, Urinary | 1 | 2017 | 14 | 0.130 |
Why?
| | Cystitis | 1 | 2017 | 22 | 0.130 |
Why?
| | Drug Monitoring | 1 | 2018 | 218 | 0.130 |
Why?
| | Fluoroquinolones | 1 | 2017 | 51 | 0.130 |
Why?
| | Retrospective Studies | 5 | 2021 | 15657 | 0.130 |
Why?
| | Escherichia coli | 2 | 2019 | 815 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 373 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 364 | 0.120 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2015 | 29 | 0.120 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2016 | 141 | 0.110 |
Why?
| | Male | 11 | 2024 | 67762 | 0.110 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2014 | 42 | 0.110 |
Why?
| | Public Health | 1 | 2019 | 588 | 0.110 |
Why?
| | Medication Therapy Management | 1 | 2015 | 76 | 0.110 |
Why?
| | Healthcare Disparities | 1 | 2020 | 654 | 0.110 |
Why?
| | Soft Tissue Infections | 1 | 2014 | 37 | 0.110 |
Why?
| | Adult | 7 | 2024 | 37929 | 0.110 |
Why?
| | Infection Control | 1 | 2015 | 167 | 0.100 |
Why?
| | Immunophenotyping | 1 | 2014 | 318 | 0.100 |
Why?
| | Drug Prescriptions | 1 | 2015 | 245 | 0.100 |
Why?
| | Global Health | 1 | 2016 | 386 | 0.100 |
Why?
| | Pediatrics | 1 | 2020 | 1101 | 0.100 |
Why?
| | Cross Infection | 1 | 2015 | 256 | 0.100 |
Why?
| | Anti-HIV Agents | 2 | 2016 | 778 | 0.100 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1477 | 0.090 |
Why?
| | Quality Improvement | 1 | 2020 | 1178 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1639 | 0.090 |
Why?
| | Infant | 3 | 2020 | 9465 | 0.090 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2011 | 38 | 0.090 |
Why?
| | Receptors, CCR5 | 1 | 2011 | 56 | 0.090 |
Why?
| | CD4 Antigens | 1 | 2011 | 141 | 0.090 |
Why?
| | Middle Aged | 7 | 2024 | 33479 | 0.090 |
Why?
| | HLA-DR Antigens | 1 | 2011 | 228 | 0.080 |
Why?
| | Internship and Residency | 1 | 2020 | 1147 | 0.080 |
Why?
| | T-Lymphocyte Subsets | 1 | 2011 | 417 | 0.080 |
Why?
| | Membrane Glycoproteins | 1 | 2011 | 500 | 0.070 |
Why?
| | Patient Discharge | 1 | 2015 | 897 | 0.070 |
Why?
| | Lung Diseases | 2 | 2024 | 767 | 0.070 |
Why?
| | RNA, Viral | 1 | 2011 | 656 | 0.070 |
Why?
| | Gene Expression Profiling | 1 | 2014 | 1774 | 0.070 |
Why?
| | Child, Preschool | 3 | 2020 | 11074 | 0.070 |
Why?
| | Health Services Accessibility | 1 | 2015 | 986 | 0.070 |
Why?
| | Aged | 3 | 2021 | 23961 | 0.070 |
Why?
| | Adolescent | 4 | 2024 | 21513 | 0.060 |
Why?
| | Hospitalization | 1 | 2015 | 2199 | 0.060 |
Why?
| | Child | 3 | 2020 | 21935 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2020 | 7635 | 0.040 |
Why?
| | Program Evaluation | 2 | 2015 | 898 | 0.040 |
Why?
| | Travel | 1 | 2020 | 130 | 0.040 |
Why?
| | Blood Group Antigens | 1 | 2019 | 15 | 0.040 |
Why?
| | Capsid | 1 | 2019 | 93 | 0.040 |
Why?
| | Capsid Proteins | 1 | 2019 | 94 | 0.040 |
Why?
| | Needs Assessment | 1 | 2020 | 376 | 0.040 |
Why?
| | Colorado | 2 | 2020 | 4565 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2020 | 6079 | 0.030 |
Why?
| | Prevalence | 1 | 2024 | 2734 | 0.030 |
Why?
| | Crystallography, X-Ray | 1 | 2019 | 476 | 0.030 |
Why?
| | Health Status Disparities | 1 | 2020 | 289 | 0.030 |
Why?
| | Treatment Failure | 1 | 2018 | 356 | 0.030 |
Why?
| | Epitopes | 1 | 2019 | 479 | 0.030 |
Why?
| | Cephalosporins | 1 | 2017 | 48 | 0.030 |
Why?
| | Organizational Policy | 1 | 2017 | 84 | 0.030 |
Why?
| | Young Adult | 2 | 2024 | 13209 | 0.030 |
Why?
| | Binding Sites | 1 | 2019 | 1303 | 0.030 |
Why?
| | Drug Resistance, Bacterial | 1 | 2017 | 186 | 0.030 |
Why?
| | Botswana | 1 | 2015 | 9 | 0.030 |
Why?
| | National Health Programs | 1 | 2015 | 23 | 0.030 |
Why?
| | Odds Ratio | 1 | 2018 | 1070 | 0.030 |
Why?
| | Drug Utilization Review | 1 | 2015 | 57 | 0.030 |
Why?
| | Drug Resistance, Microbial | 1 | 2015 | 71 | 0.030 |
Why?
| | Time | 1 | 2015 | 83 | 0.030 |
Why?
| | Inappropriate Prescribing | 1 | 2015 | 55 | 0.030 |
Why?
| | Population Surveillance | 1 | 2018 | 482 | 0.030 |
Why?
| | Hypokalemia | 1 | 2014 | 24 | 0.030 |
Why?
| | Community-Institutional Relations | 1 | 2015 | 98 | 0.030 |
Why?
| | Cohort Studies | 1 | 2024 | 5742 | 0.030 |
Why?
| | Safety Management | 1 | 2015 | 124 | 0.030 |
Why?
| | Pneumonia, Bacterial | 1 | 2015 | 116 | 0.030 |
Why?
| | Patient Care | 1 | 2015 | 111 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 1007 | 0.030 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2017 | 261 | 0.030 |
Why?
| | Drug Combinations | 1 | 2014 | 343 | 0.030 |
Why?
| | Community-Acquired Infections | 1 | 2015 | 174 | 0.020 |
Why?
| | Urinary Tract Infections | 1 | 2015 | 188 | 0.020 |
Why?
| | Protein Binding | 1 | 2019 | 2224 | 0.020 |
Why?
| | Ambulatory Care | 1 | 2017 | 546 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3457 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1587 | 0.020 |
Why?
| | Lymph Nodes | 1 | 2011 | 491 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2018 | 10811 | 0.010 |
Why?
| | Risk Factors | 1 | 2014 | 10388 | 0.010 |
Why?
|
|
Haas's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|